1 / 7

PROCESS VALIDATION - ACTUAL REGULATION, PERFORMING AND INSPECTION

Explore the Eurasian Economic Commission’s decision №77 revision, aligning Annex 15 with ICH principles (Q8, Q9, Q10) with emphasis on pharmaceutical development and quality systems. Key changes discussed include documentation, qualification, and new sections like ongoing process verification. Major revisions in process and cleaning validation sections are highlighted, along with harmonization efforts with decision №19 for toxicological evaluation and validation approaches. The narrative also flags common deficiencies in manufacturing process and cleaning validation, emphasizing the importance of risk-based assessments and scientific knowledge.

camador
Download Presentation

PROCESS VALIDATION - ACTUAL REGULATION, PERFORMING AND INSPECTION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PROCESS VALIDATION - ACTUAL REGULATION, PERFORMING AND INSPECTION

  2. Eurasian Economic Commission​​ decision № 77 new revision • Annex 15 harmonization with EMA regulation • Main idea: inclusion of the principles ofICH (Q8, Q9, Q10) in Annex 15. • ICH Q8 Pharmaceutical Development • ICH Q10 Pharmaceutical Quality System • ICH Q8 Pharmaceutical Development • ICH Q9 Quality Risk Management Knowledge management Design space Risk-based approaches

  3. Eurasian Economic Commission​​ decision № 77 new revision • Key changes in Annex 15: • Documentation • Qualification • Process and Cleaning Validation • New sections: • Ongoing Process Verification during Lifecycle • Verification of Transportation • Validation of Packaging • Qualification of Utilities • Validation of Test Methods Planning and documentation for Qualification and Validation Added information on the qualification stages Major revision of the Process and Cleaning Validation sections

  4. Manufacturing process validation Cleaning Validation Harmonization withEurasian Economic Commission​​ decision № 19 Toxicological evaluation Prospective validation Traditional approach Appropriate number of times based on a risk assessment Continuous Process Verification Hybrid Approach Concurrent validation Where there is strong risk – benefit to the patient Retrospective validation? Not acceptable!

  5. Deficiencies • There are no manufacturing process validation or cleaning validation. • There are no justification for concurrent process validation approach. • There are no justification for CPP’s. • The evaluation of the risk to quality is not based on scientific knowledge, experience with the process. • Cleaning validation was performed with out toxicological evaluation.

  6. Deficiencies • Cleaning validation was performed with out microbiological or bacterial endotoxins consideration. • There are no drug product testing results in manufacturing process validation report. • Less than three consecutive batches were manufactured during manufacturing process validation. • There are no results for few acceptance criteria mentioned in validation protocol.

  7. Thank you! QUESTIONS PLEASE!

More Related